Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C (Business Wire via Yahoo! Finance) by Allergy and asthma associate

Tue, 09 Oct 2007 07:08:32 -0400

Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C (Business Wire via Yahoo! Finance)

by Allergy and asthma associate @ Tue, 09 Oct 2007 07:08:32 -0400
CAMBRIDGE, Mass.----Idera Pharmaceuticals today announced that the first patient has been dosed in a Phase 1 trial evaluating IMO-2125 for the treatment of patients with hepatitis C virus infection.

DOR BioPharma Announces Initiation of GI Radiation Injury Program Pursuant to $1 Million NIH Grant (Marketwire via Yahoo! Finance)
DOR BioPharma, Inc. announced today that its academic partner, the Fred Hutchinson Cancer Research Center, has received a $1 million grant from the National Institute of Health to conduct preclinical studies of oral Beclomethasone Dipropionate for the treatment of gastrointestinal radiation injury.